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The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 
deaths in China.  Because of the lack of existing immunity against H7 subtype influenza viruses 
in the human population and the absence of a licensed commercial vaccine, antiviral drugs are 
critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers 
and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The 
emerging H7N9 viruses are resistant to the	 M2-ion channel blockers because of a S31N mutation 
in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K 
substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that 
Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is 
approved for clinical use, this would allow a rapid regulatory approval process for this drug 
under pandemic threat. 
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Emergence of the novel H7N9  
 
A new deadly influenza A H7N9 strain of avian influenza virus, first identified in China in 
March 2013 with human and avian cases, has been observed in various eastern and inland 
Chinese provinces[1, 2]. There have been a total of 132 confirmed cases with 43 deaths with 
people over 60 appearing to be more susceptible to the H7N9-associated severe respiratory 
disease[3-6]. Patients infected by H7N9 have exhibited viral pneumonia, acute kidney failure, 
acute respiratory distress syndrome, diffuse intravascular coagulation and septic shock. Although 
the H7N9 subtype can be highly virulent in humans, it exhibits low pathogenicity in avian hosts 
perhaps due in part to the absence of a multi-basic amino acid sequence at the hemagglutinin 
cleavage site[1, 7, 8]. Infected chickens, however, can shed virus very efficiently via the 
oropharynx, and we and others have observed limited shedding by the cloacal route despite no 
clinical signs of infection (unpublished data; Liu et al. and [9]). This unusual low pathogenicity 
of the avian H7N9 viruses makes an H7N9 infection in avian species hard to detect and to 
monitor. Experts remain fearful of the potential for this virus to mutate into a form easily 
transmissible between humans, although to date, there has been no clear confirmation of human-
to-human transmission[4].   
 
Genetic analysis shows that the novel H7N9 virus is a triple reassortant virus carrying genes 
from H7N3, H9N2 and H11N9 or H2N9 avian influenza A viruses. It is assumed that the novel 
H7N9 subtype virus was generated by a single or double independent reassortment event in 
ducks or chickens in China[10]. Most of the H7N9 viruses carry certain mammalian adaptation 
signatures (i.e. PB2-627K, HA-226L), which have been proved critical in mammalian adaption 
and transmission based on previous studies[11] and especially the 226L in the H7 HA protein 
based on our unpublished data (Liu et al. submitted). Virulence and transmissibility of this novel 
H7N9 influenza virus have been characterized in different mammalian animal models, including 
mice, ferrets, macaques and pigs[7, 9, 12-14]. In ferrets, the H7N9 virus showed transmission by 
direct contact among ferrets and limited transmissibility by respiratory droplets[7, 12-14]. 
Moreover, the novel H7N9 virus replicated efficiently in both upper and lower respiratory tracts 
of infected nonhuman primates (cynomolgus macaques). Emergent H7N9 viruses isolated from 




H9N2 viruses and genetically related H7N9 viruses isolated from wild birds before 2013[7, 12]. 
Swine are an important intermediate host for influenza viruses[15]; one of the concerns is that of 
H7N9 viruses may jump into pigs, they might replicate efficiently in this host, adapt to the 
mammalian receptor repertoire and reassort with endemic swine influenza viruses. Previous 
studies showed that pigs infected intranasally with H7N9 viruses did not transmit virus to contact 
pigs[14], while pigs infected intratracheally with H7N9 can transmit to sentinel animals with low 
efficiency (Liu et al., submitted). These facts warrant increased surveillance for H7N9 influenza 
viruses in pigs. 
 
Antivirals and Tamiflu® resistance of the novel H7N9 virus  
 
The novel H7N9 virus rapidly spread over a large geographic region in China after the first 
reported case in March 2013 with the live poultry markets thought to be the source of human 
infections, suggesting that H7N9 viruses might be silently prevalent in  poultry in China[10]. 
Continuing detection in poultry and sporadic human infections raises concerns on the emergence 
of a H7N9 virus, which can efficiently transmit between humans. Vaccination is a very efficient 
way to prevent influenza infection; however, no commercial vaccine specific for H7N9 is 
currently available. Moreover, humans lack any immunological memory against H7N9, which is 
another concern of its potential to result in a pandemic if easy human to human transmission is 
acquired. 
Antiviral treatment is an important strategy in helping to control and prevent influenza 
infections. As recommended by the CDC in Atlanta, USA, antiviral treatment against influenza 
infections should be applied as early as possible, ideally within 48 hours after onset of illness. 
Antiviral drugs are readily available to treat influenza infections including this novel H7N9 
virus. For influenza infections, M2-ion channel blockers (e.g., amantadine and rimantadine) and   
neuraminidase inhibitors (e.g., oseltamivir, zanamivir, and peramivir) have been mainly used as 
antiviral drugs and those compounds are approved by the Food and Drug Administration (FDA) 
[16, 17]. However, the H7N9 is resistant to both amantadine and rimantadine because a S31N 
mutation exists in the M2 protein, which confers M2-ion channel blocker resistance[18]. 




used for the treatment of the novel H7N9 infection and other M2-ion channel blocker resistant 
influenza viruses[19].  
 
Clinical studies show that oseltamivir treatment reduces the viral load in the respiratory tract of 
patients with H7N9 infection[5]. However, some patients with oseltamivir treatment failure had a 
poor clinical outcome. Further studies on the H7N9 viruses isolated from those patients showed 
that an R292K substitution occurred in the NA protein; this NA change is associated with 
resistance to all neuraminidase inhibitors including oseltamivir (Tamiflu®)[20]. Surprisingly, in 
humans treated with oseltamivir, the R292K substitution occurred as early as 2 days post 
treatment with the 292K genotype becoming the predominant virus population at 7 days post 
treatment. Neuraminidase inhibition assays using the resistant H7N9 virus showed 100-fold and 
30-fold reduced susceptibility to the two FDA approved inhibitors, oseltamivir and zanamivir, 
respectively[5]. Subsequently, neuraminidase inhibitor resistance of H7N9 viruses in humans 
resulted in antiviral treatment failure and a poor clinical outcome. Further studies confirmed that 
H7N9 isolates with a dominant 292K genotype are resistant to zanamivir, peramivir, and 
oseltamivir, although this resistance can be masked by a mixed R/K genotype on position 292 of 
the NA protein in a viral quasispecies population[21]. Rapid emergence of antiviral drug 
resistant mutants after treatment with oseltamivir or zanamivir is raising concerns about the 
prevalence of such resistant H7N9 viruses in the humans and other mammalian populations. This 
emphasizes the importance of the development of new antiviral influenza drugs or the use of 
already developed FDA approved drugs for other infectious diseases, which might also work 
against influenza. Other influenza antivirals are under development, including thiazides that are 
anti-influenza molecules targeting the viral hemagglutinin at the post-translational level[22]; 
Favipiravir (T-705), a novel viral RNA polymerase inhibitor[23]; Aprotinin, a protease inhibiting 
the cleavage of the HA protein[24]. None of these compounds, however, have been approved for 
clinical treatment for influenza infection. 
 
Alferon N inhibits replication of oseltamivir resistant and sensitive H7N9 viruses in vitro  
 
Type I interferons (IFN) including IFN alpha and beta produced by host cells in response to the 
presence of viral pathogens, play a critical role in pathogen clearance during infection[25]. 




are highly sensitive to the antiviral actions of type I IFNs [26, 27]. Type I IFN upregulates the 
expression of several IFN-stimulated antiviral gene products, such as protein kinase R (PKR), 
2’,5’-oligoadenylate synthetase (OAS) and the Mx protein[28]. The activated PKR 
phosphorylates the eukaryotic initiation factor eIF2α, thereby inhibiting viral mRNA translation 
and viral replication[29]. OAS inhibits viral protein synthesis[28]; and the Mx protein interacts 
with viral components to block generation of new virus particles[26, 30].  
 
Alferon N (IFN-α-n3) is a natural IFN alpha product derived from human leukocytes. In previous 
studies using SARS virus, Alferon N was the only IFN-based drug to be active against SARS 
virus at clinically achievable serum levels with the failure of other tested IFN-based clinical 
products [31]. Additionally Alferon N has a better safety profile than recombinant IFNs [32]. We 
tested antiviral activity of Alferon N against the novel H7N9 virus in human alveolar epithelial 
cells (A549) using two human H7N9 isolates: A/Anhui/1/2013 (Anhui/1/H7N9) and 
A/Shanghai/1/2013 (Shanghai/1/H7N9). Both viruses were isolated from human cases in China. 
Sequence information showed that the Anhui/1/H7N9 contains the NA-292R residue and is 
sensitive to NA inhibitors; in contrast, the Shanghai/1/H7N9 contains a NA-292K residue that is 
associated with resistance to NA inhibitors. The genetic signatures of both viruses are 
summarized in Table. 1. Oseltamivir (Tamiflu®), an NA inhibitor, was tested on A549 cell as a 
well-known and widely used anti-influenza drug. 
  
Confluent A549 cells in 48-well plates were treated with different units of Alferon N (10,000 
IU/ml, 1,000 IU/ml, 100 IU/ml obtained from Hemispherx Biopharma) for 4 hours before 
infection, and untreated cells served as controls; Thereafter, both Alferon N treated and untreated 
A549 cells were infected with the Anhui/1/H7N9 and Shanghai/1/H7N9 viruses at a multiplicity 
of infection (MOI) of 0.01 under BSL3/BSL3Ag conditions. Combination of a short natural IFN-
 pre-incubation and a MOI of 0.01 simulate the conditions of an in vivo natural infection. A 
relatively small number of cells are initially infected resulting in the induction of Type 1 IFNs 
that in turn induce innate immune responses in uninfected cells. The supernatants were collected 
at 12 hours, 24 hours, 36 hours and 48 hours post infection and titrated for virus content on 
MDCK cells in 96-well plates as described previously[33]. For comparison, Oseltamivir 




concentration of 0.3 µg/ml, 0.2 µg/ml, 0.1 µg/ml and 0.01 µg/ml with treatment starting at the 
time of infection.  
 
The results showed that oseltamivir (Tamiflu®) was able to inhibit the replication of NA inhibitor 
sensitive Anhui/1/H7N9 virus at a concentration ranging from 0.1 µg/ml to 0.3 µg/ml (Figure 
1A); in contrast, oseltamivir (Tamiflu®) treatment with the same doses did not inhibit the NA 
inhibitor resistant Shanghai/1/H7N9 virus, confirming that the 292K residue in NA of 
Shanghai/1/H7N9 conferred resistance to oseltamivir. Antiviral activity of Alferon N was found 
against both the Shanghai/1/H7N9 and Anhui/1/H7N9; clear inhibition of virus replication was 
found at 36 and 48 hours post infection (Figure 1B). Alferon N with a concentration of 10,000 
IU/ml significantly reduced Anhui/1/H7N9 virus load at 36 hours post infection, and all three 
doses (100 IU/ml, 1000 IU/ml and 10,000 IU/ml) significantly inhibit replication of oseltamivir 
sensitive Anhui/1/H7N9 and oseltamivir resistant Shanghai/1/H7N9 at 48 hours post infection 
(Figure 1B). Our data demonstrates that Alferon N is effective against both oseltamivir sensitive 
and resistant H7N9 viruses and provides sufficient evidence to justify the costly in vivo studies 
(BSL3/BSL3Ag) required for regulatory approval.   
  
Expert commentary and five-year view 
The emergence of NA inhibitor resistant strains of the novel H7N9 virus in treated patients 
requires alternative antiviral compounds for human therapy, which will be critical in case of a 
potential pandemic. Our results show that both oseltamivir (Tamiflu®) and Alferon N have 
significant inhibitory effect on the NA inhibitor sensitive H7N9 virus. In contrast, Alferon N, not 
Tamiflu®, had an inhibitory effect on the neuraminidase resistant Shanghai/1/H7N9 virus.  These 
results provide evidence for a new therapeutic strategy to mitigate the public health hazards 
associated with H7N9 infection in humans and the potential spread of NA inhibitor resistant 
H7N9 and other influenza viruses of potential high virulence for humans. 
The emergence of influenza pandemic is unpredictable. No universal influenza vaccine is 
available so far. The licensed anti-influenza drugs (M2-ion channel blockers and neuraminidase 
inhibitors) are limited in clinical treatment of infected patients because of rapid emergence of 




pandemic is high mortality (e.g. H5N1, H7N9). The rapid disease progression characteristic of 
pandemic influenza viruses and the emergence of resistance to inhibitors of viral function will 
require other approaches to limit or terminate disease and spread of the virus. In addition to the 
rapid regulatory approval of Alferon N or other anti-influenza drugs for this indication, the 
development of novel anti-influenza drugs using different mechanisms or targeting at different 
genes (e.g. polymerase genes, nucleoprotein gene and hemagglutinin  gene etc.), innate immune 
responses, and/or combination therapy is necessary for better pandemic defense.  
Key Issues 
 Antiviral treatment is an important strategy in controlling and preventing influenza viral 
infections. Current pharmaceuticals approved for the prophylaxis and/or treatment of 
influenza inhibit the function of the neuraminidase and M2 ion channel viral proteins. 
 High mutational rates are characteristic of influenza viruses resulting in viruses with 
resistance to neuraminidase or M2 inhibitors. Such viruses present a high-risk human 
public health threat for emerging avian influenza viruses with high pathogenicity for 
humans such as H7N9. 
 Some H7N9 isolates have gained resistance to neuraminidase inhibitors. Alferon N 
(natural interferon) has broad anti-viral activities and inhibits the replication of both wild 
type and neuraminidase inhibitor resistant H7N9 viruses. 
 An imminent pandemic threat from H7N9 or other avian influenza viruses with resistance 
to neuraminidase and M2 inhibitor demands research on novel anti-influenza drugs 
targeting different viral genes and/or innate immune responses. 
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Figure 1. Sensitivity of human H7N9 influenza viruses to Tamiflu® and Alferon N in vitro. 
A549 cells were infected with Shanghai/1/H7N9 (containing K at NA residue 292) or 
Anhui/1/H7N9 (containing R at NA residue 292) viruses at MOI of 0.01. Supernatants were 
collected at 12, 24, 36 and 48 hours post infection and were titrated in MDCK cells, all studies 
were conducted in BSL3/BSL3Ag laboratory located at Biosecurity Research Institute 
(BSL3/BSL3Ag) located at Kansas State University. All data were analyzed by using analysis of 
variance (ANOVA) in GraphPad Prism version 5.0 (GraphPad software Inc, CA); a P-value < 
0.05 was considered statistically significant. Bars represent the mean values ± SEM for 3 
independent replicates. (*: p<0.05; **: p<0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
